Insights Into Intestinal Flora in Metabolic Dysfunction‐Associated Steatotic Liver Disease
The FASEB Journal · 2025
DOI: 10.1096/fj.202403293rr ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, 2025. Verfasst von Zechen Xin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medical Sciences, Peking University. NHC Key Laboratory of Medical Immunology (Peking University), Beijing,…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease, Dysbiosis, Fatty Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 145 Literaturangaben. Gefördert von: Beijing Life Science Academy (BLSA), the National Natural Science Foundation of China, the Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a metabolic disease characterized by excessive accumulation of liver fat, encompassing nonalcoholic fatty liver (NAFL) and metabolic dysfunction‐associated steatohepatitis (MASH), which is among the rapidly proliferating diseases globally. MASLD disrupts the normal structure and function of the liver, resulting in liver fibrosis, cirrhosis, and ultimately hepatocellular cancer and other severe outcomes. Recent investigations have demonstrated that intestinal flora significantly influence the development of MASLD. The proliferation of intestinal flora in the context of MASLD exacerbates the dysbiosis of intestinal flora. Dysbiosis of intestinal microbiota impairs the intestinal barrier, facilitating the translocation of intestinal flora and its metabolites into the portal circulation, resulting in hepatic injury and the subsequent onset of MASLD. Furthermore, intestinal flora facilitates the onset of NAFLD through endotoxin production and involvement in bile acid metabolism. The possible regulating function of additional intestinal flora‐related metabolites in MASLD has garnered heightened interest. Herein, we outline the probable relationship between intestinal flora and MASLD, highlighting the significant research value and developmental possibilities of novel pharmacological interventions aimed at intestinal microbiota for the treatment of MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, School of Basic Medical Sciences, Peking University. NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
- School of Pharmacy, Binzhou Medical University, Yantai, China.
ORCID-Profile: Zechen Xin, Ziyuan Wang
Förderung
- Beijing Life Science Academy (BLSA)
- the National Natural Science Foundation of China
- the Natural Science Foundation of Beijing Municipality
- the Peking University Medicine Seed Fund for Interdisciplinary Research
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Xin, Z., Wang, Z., & Chu, M. (2025). Insights Into Intestinal Flora in Metabolic Dysfunction‐Associated Steatotic Liver Disease. The FASEB Journal. https://doi.org/10.1096/fj.202403293rr
Vancouver
Xin Z, Wang Z, Chu M. Insights Into Intestinal Flora in Metabolic Dysfunction‐Associated Steatotic Liver Disease. The FASEB Journal. 2025. doi:10.1096/fj.202403293rr
BibTeX
@article{Xin2025,
author = {Xin, Zechen and Wang, Ziyuan and Chu, Ming},
title = {Insights Into Intestinal Flora in Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202403293rr}
}
EUVIMED